Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Deals & M&A

Rosemont to buy Aytu in roughly $56m cash deal

Aytu has agreed to a $2.70-a-share offer from Rosemont Pharmaceuticals Holdings, announced with quarterly results showing a sales rise and a persistent net loss.

16 Nov 2026 · Aytu Biopharma, Inc AYTU · Company news

Rosemont Pharmaceuticals Holdings has agreed to acquire Aytu BioPharma for $2.70 per share in cash, a deal the companies value at about $56m. The transaction is structured as a tender offer, in which the buyer makes its offer directly to shareholders. Closing is expected by the end of 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Aytu Biopharma, Inc ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Deals & M&AAll →